Short Interest in NewAmsterdam Pharma (NASDAQ:NAMS) Rises By 156.4%

NewAmsterdam Pharma (NASDAQ:NAMS) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 2,590,000 shares, a growth of 156.4% from the November 15th total of 1,010,000 shares. Currently, 6.0% of the company’s stock are sold short. Based on an average daily trading volume, of 567,700 shares, the days-to-cover ratio is presently 4.6 days.

Analyst Ratings Changes

Several brokerages recently commented on NAMS. Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Scotiabank upped their price target on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $36.20.

NewAmsterdam Pharma Stock Down 1.6 %

Shares of NAMS opened at $24.69 on Friday. NewAmsterdam Pharma has a 12-month low of $9.72 and a 12-month high of $27.29. The business has a 50-day simple moving average of $20.53 and a two-hundred day simple moving average of $18.72.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 45,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $25.02, for a total value of $213,420.60. Following the completion of the transaction, the insider now directly owns 11,812,033 shares in the company, valued at $295,537,065.66. This represents a 0.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 86,803 shares of company stock valued at $1,755,307. 19.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently made changes to their positions in NAMS. Frazier Life Sciences Management L.P. increased its stake in shares of NewAmsterdam Pharma by 5.1% in the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock valued at $213,396,000 after buying an additional 628,251 shares during the period. Janus Henderson Group PLC boosted its position in shares of NewAmsterdam Pharma by 51.1% during the 3rd quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock valued at $25,607,000 after purchasing an additional 520,772 shares in the last quarter. Decheng Capital LLC bought a new stake in shares of NewAmsterdam Pharma during the 2nd quarter valued at about $7,684,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of NewAmsterdam Pharma by 1,231.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock valued at $3,972,000 after purchasing an additional 221,305 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of NewAmsterdam Pharma by 23.0% during the 2nd quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after purchasing an additional 217,902 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.